Atlas Venture

Atlas Venture is a leading Boston-based venture capital firm that seeded and co-founded Intellia. It invests in early stage biotech companies with innovative therapeutics and creates value by identifying cutting-edge science and helping translate it into potentially transformative medicines. Since 2012, Atlas Venture has co-founded and/or helped launch 20 new biotech seed-stage startups, with the vast majority focused on first-in-class breakthrough medicines.

Orbimed Healthcare Fund Management

From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. OrbiMedĀ has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. ItsĀ team of over 80 distinguished scientific, medical, investment and other professionals manage approximately $15 billion across public and private company investments worldwide


Intellia has a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CAR-Ts) and hematopoietic stem cells (HSCs).

The partnership will enable Intellia to develop its own proprietary internal HSC pipeline with Novartis receiving exclusive rights to develop all collaboration programs focused on engineered CARTs. Under the terms of the agreement, Novartis increased its equity investment in Intellia and will provide technology access fees and funding for R&D programs during the term of the collaboration. Intellia is also eligible to receive downstream success-based milestones and royalties.

Novartis is a global healthcare company based in Basel, Switzerland.

Additional Key Investors

Fidelity Management and Research Company

ECOR1 Capital

Foresite Capital

Janus Capital Management

Sectoral Asset Management